TriStar Technology Ventures Invests in GenomOncology
News Feb 06, 2014
GenomOncology has announced the investment from TriStar Technology Ventures, a healthcare innovation venture firm, as well as the appointment of John Doulis, CIO of TriStar’s partner fund, MedCare Investment Funds, to the company’s Board Of Directors.
As Chief Information Officer of MedCare, Dr. Doulis brings 20 years of experience as a physician, executive, scientist, and architect and manager of healthcare information systems.
Prior to MedCare, Dr. Doulis was Assistant Vice Chancellor and Chief Operations Officer of the Informatics Center at Vanderbilt University, leading the Informatics Center’s efforts to provide the most effective information technology infrastructure possible to the diverse operating units within VUMC.
John Doulis joins current GenomOncology Board members Manuel J. Glynias, President and CEO of GenomOncology, Bradley Wertz, former President and COO of Rosetta, and Lee Zapis, principal of Zapis Capital Group.
“We are very pleased to welcome Dr. Doulis to our Board of Directors,” said Manuel Glynias, President and CEO of GenomOncology. “His strong healthcare and informatics experience will compliment the expertise of our other Board members, ensuring that GenomOncology will be prepared to fully leverage the opportunities presented by this very dynamic market.”
“As the use of NGS data transitions from the research lab to the bedside, GenomOncology’s innovative technology and business model position the company to accelerate this transformation,” said Dr. Doulis. “I look forward to helping GenomOncology achieve its full potential.”
Brian Laden, Partner and Vice President at TriStar Technology Ventures, will join Dr. Doulis in working closely with the company. “GenomOncology has created a best-in-class product offering that allows pathologists to leverage the power of NGS without having to outsource the work to a third party or build an internal bioinformatics team. With their outstanding management team, they have positioned the company to capitalize on the rapidly expanding market for DNA-based molecular diagnostics.”
In collaboration with researchers and physicians, GenomOncology has developed two proprietary software platforms that streamline the use of NGS in medicine and research: GO Clinical Workbench™ for the clinical laboratory and GenomAnalytics™ for research applications. Software implementation occurs inside the client’s firewall, alleviating HIPAA concerns.
For the clinical laboratory, the platform is configured to each client’s specific needs with clinical systems (LIMS, EMR, etc.) integration, setting of quality control and annotation parameters, and design of the resultant clinical report. For researchers, the platform is updated on a monthly basis, adding new features and functions based on individualized research interests and use. In both environments, GenomOncology provides onsite experts in bioinformatics and genomics to leverage the platform to support each client’s current and future needs.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.